Stock AnalizSanofi SNY
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Sanofi (SNY) is a healthcare company listed in the US with a market value of about $118.0B. In the twelve months to September 30, 2026 it had revenue of $56.2B and net income of $4.6B, a net margin of 8.2%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is financial health (5/5); the weakest is track record (1/5).
Key numbers: a P/E of 25.3, a price to free cash flow of 12.7, 5-year revenue growth of 3% a year, a 5-year average ROIC of 7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 19% above the current price.
Score: 2.8 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $56.2B | $51.3B | $42.7B | $41.8B | $40.2B | $42.8B | $44.2B | $40.6B | $39.5B | $42.1B | $35.6B |
| Net income | $4.6B | $9.2B | $5.8B | $6.0B | $8.9B | $7.0B | $15.1B | $3.1B | $4.9B | $10.1B | $5.0B |
| Free cash flow | $9.3B | $8.5B | $6.1B | $8.1B | $9.0B | $9.6B | $6.5B | $6.7B | — | — | — |
| EPS (diluted) | $1.91 | $3.76 | $2.37 | $2.45 | $3.66 | $2.89 | $6.19 | $1.27 | $2.02 | $4.14 | $2.04 |
| Net margin | 8.2% | 17.9% | 13.5% | 14.3% | 22.2% | 16.5% | 34.1% | 7.6% | 12.5% | 24.0% | 13.9% |
| ROIC | — | 5.6% | 6.1% | 6.1% | 8.5% | 7.2% | 13.0% | 2.9% | 4.4% | 6.2% | 6.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Sanofi’s P/E ratio?
About 25.3, based on the last twelve months of diluted earnings per share (forward P/E about 8.9).
Is Sanofi stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 19% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Sanofi pay a dividend?
Yes. The dividend yield is about 4.99%, and it has paid dividends for 10 years in our data.
Is Sanofi a good stock to buy?
We do not give buy or sell advice. Sanofi scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.